Quest Diagnostics stock (US74834L1008): trading near upper half of 52-week range as technical picture stays balanced

Quest Diagnostics shares on the New York Stock Exchange were recently quoted around the upper half of their 52-week range, with the diagnostic-testing specialist moving only modestly in recent sessions and no new corporate announcements since its latest quarterly results, keeping attention on the broader US healthcare backdrop rather than a single headline catalyst.

The stock most recently closed at USD 194.78 on 05/29/2026 on the NYSE under the ticker DGX, down 0.72% for that session, according to MarketBeat data as of that date.MarketBeat as of 05/29/2026 This places the company comfortably above the lower end of its 52-week trading band of USD 164.65 to USD 213.50, based on figures from Investing.com cited on 05/31/2026.Investing.com as of 05/31/2026

With its primary listing in the United States on the NYSE and inclusion in major US healthcare-related benchmarks, Quest Diagnostics remains a key name for investors tracking diagnostic services and laboratory testing exposure in the home market. In Germany, the shares can also be traded via various secondary venues such as Tradegate, providing euro-denominated access for European investors alongside the core US dollar line in New York.

The company has not reported any new SEC filings announcing transformative M&A, divestitures, or capital actions in the past weeks, and there have been no disclosed changes to its dividend policy or share repurchase programs over the last 90 days on the main investor-relations and regulatory channels. As a result, recent trading has been guided mainly by sector sentiment, interest-rate expectations, and positioning in US healthcare equities rather than a specific company event.

As of: 05/31/2026

By the editorial team - specialized in equity coverage.

Quest Diagnostics: core business model

Quest Diagnostics focuses on providing a broad portfolio of clinical laboratory and diagnostic information services, generating most of its revenue from processing tests and delivering results for physicians, hospitals, health systems, and employers across the United States.

Chart technicals and 52-week range

From a technical perspective, Quest Diagnostics is trading within a 52-week range of USD 164.65 to USD 213.50, based on data compiled by Investing.com as of 05/31/2026, placing the latest close of USD 194.78 roughly in the upper half of that corridor.Investing.com as of 05/31/2026 Over the past 12 months, this corresponds to a price gain of about 12.44%, indicating the shares have outperformed their own lower bound but remain below the 52-week peak cited in the same dataset.

Short-term daily moves have recently stayed inside a relatively narrow band around the USD 190 to USD 200 area, according to recent NYSE closing data reported by MarketBeat on 05/29/2026, which suggests a period of consolidation after earlier advances.MarketBeat as of 05/29/2026 While specific indicators such as moving averages or momentum oscillators are not disclosed in these sources, the combination of a positive one-year change and a position below the 52-week high paints a neutral-to-balanced technical setup rather than an extreme condition.

Conclusion

Quest Diagnostics is currently trading in the upper half of its 52-week band, with the latest NYSE close of USD 194.78 leaving the shares below their one-year high but well above the lows, and with no major new company-specific announcements since the last quarterly update. The technical profile, built on a 12.44% one-year price increase and a consolidating trading range, provides a neutral backdrop for investors following US healthcare diagnostics. How the stock performs from here will likely depend on upcoming earnings disclosures, sector sentiment, and broader macroeconomic factors influencing US equity markets.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.